Eisai Co., Ltd. is taking the early lead on the US commercial effort for Leqembi (lecanemab) in Alzheimer’s disease, but the company’s partner,Biogen, Inc., will add reinforcement – as long as the drug has approval for reimbursement from the Centers for Medicare and Medicaid Services (CMS) following full approval by the US Food and Drug Administration.
CMS Approval Will Mark ‘Starting Gate’ For Leqembi Launch For Biogen
Biogen will likely add sales reps to support Eisai’s US commercial launch of the Alzheimer’s drug early next year when treatment capacity increases.
More from Neurological
• By
Eisai is working on securing reimbursement across the EU for Leqembi now that the Alzheimer’s disease treatment has secured marketing approval from the European Commission.
• By
The pact could be worth more than $2.6bn and adds to growing big pharma investment in the technology.
• By
By allowing it to enter the brain more easily, trontinemab’s brain shuttle brings more patients to ‘amyloid zero’ levels faster, and with fewer brain swelling side effects.
• By
The study’s failure in the overall MDD population was not a surprise, but solriamfetol’s efficacy in MDD with EDS provided a rationale for testing it in that subpopulation.
More from Therapy Areas
• By
The biotech reported Phase I multiple-ascending dose data for its obesity drug for the second time in a week, but its safety and tolerability do not offset concerns about relatively unimpressive weight reduction.
• By
Regeneron is disappointed by the knock-back for longer dosing intervals for its high-dose version of Eylea, but its supplemental application for a more commercially important shorter four-week regimen has received a priority review.
• By
The company reported positive topline results for ASCENT-04, which also bode well for the ASCENT-03 trial in patients with low PD-L1 expression.